- Home
- KIM vs RPRX Comparison
KIM vs RPRX Comparison
Compare KIM & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIM
- RPRX
- Stock Information
- Founded
- KIM 1958
- RPRX 1996
- Country
- KIM United States
- RPRX United States
- Employees
- KIM N/A
- RPRX N/A
- Industry
- KIM Real Estate Investment Trusts
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- KIM Real Estate
- RPRX Health Care
- Exchange
- KIM Nasdaq
- RPRX Nasdaq
- Market Cap
- KIM 15.0B
- RPRX 14.0B
- IPO Year
- KIM 1991
- RPRX 2020
- Fundamental
- Price
- KIM $21.52
- RPRX $33.42
- Analyst Decision
- KIM Buy
- RPRX Strong Buy
- Analyst Count
- KIM 17
- RPRX 6
- Target Price
- KIM $24.50
- RPRX $41.67
- AVG Volume (30 Days)
- KIM 4.4M
- RPRX 4.6M
- Earning Date
- KIM 02-07-2025
- RPRX 02-11-2025
- Dividend Yield
- KIM 4.69%
- RPRX 2.63%
- EPS Growth
- KIM N/A
- RPRX N/A
- EPS
- KIM 0.55
- RPRX 1.91
- Revenue
- KIM $2,037,014,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- KIM N/A
- RPRX $29.18
- Revenue Next Year
- KIM $4.04
- RPRX $9.99
- P/E Ratio
- KIM $38.77
- RPRX $17.52
- Revenue Growth
- KIM 14.22
- RPRX N/A
- 52 Week Low
- KIM $17.57
- RPRX $24.05
- 52 Week High
- KIM $25.83
- RPRX $33.69
- Technical
- Relative Strength Index (RSI)
- KIM 36.25
- RPRX 78.16
- Support Level
- KIM $21.43
- RPRX $32.28
- Resistance Level
- KIM $22.63
- RPRX $33.69
- Average True Range (ATR)
- KIM 0.46
- RPRX 0.69
- MACD
- KIM -0.05
- RPRX -0.02
- Stochastic Oscillator
- KIM 12.21
- RPRX 89.85
About KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.